Associated Papers
Oncogenic NFE2L2 mutations in plasma ctDNA and tumors are predictors and prognosticators of chemoradiation therapy in resectable esophageal squamous cell carcinoma.
Ko JM et al.
British Journal of Cancer, 2025
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography.
Greenwood HE et al.
Nature Communications, 2024
Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
Iwasaki T et al.
Cancer Science, 2024
Organismal metabolism regulates the expansion of oncogenic PIK3CA mutant clones in normal esophagus.
Herms A et al.
Nature Genetics, 2024
The small MAF transcription factor MAFG co-opts MITF to promote melanoma progression.
Vera O et al.
Biorxiv : the Preprint Server for Biology, 2024
PPIA dictates NRF2 stability to promote lung cancer progression.
Lu W et al.
Nature Communications, 2024
NRF2 mutation enhances the immune escape of hepatocellular carcinoma by reducing STING activation.
Li C et al.
Biochemical and Biophysical Research Communications, 2024
Structurally-informed human interactome reveals proteome-wide perturbations by disease mutations.
Xiong D et al.
Biorxiv : the Preprint Server for Biology, 2024
Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment.
Ngo HKC et al.
Journal of Cancer Prevention, 2023
Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
Lo A et al.
Bmc Cancer, 2022
High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients.
Jiang X et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.
Benz C et al.
Molecular Systems Biology, 2022
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.
Gutiontov SI et al.
Scientific Reports, 2021
Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J et al.
Hepatology (baltimore, Md.), 2021
Genomic profile of advanced breast cancer in circulating tumour DNA.
Kingston B et al.
Nature Communications, 2021
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Comprehensive characterization of protein-protein interactions perturbed by disease mutations.
Cheng F et al.
Nature Genetics, 2021
Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients.
Marin E et al.
Diagnostics (basel, Switzerland), 2020
A functionally defined high-density NRF2 interactome reveals new conditional regulators of ARE transactivation.
Poh J et al.
Redox Biology, 2020
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
Rare and common genetic variations in the Keap1/Nrf2 antioxidant response pathway impact thyroglobulin gene expression and circulating levels, respectively.
Matana A et al.
Biochemical Pharmacology, 2020
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L et al.
Redox Biology, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans.
Mitchell KA et al.
Nature Communications, 2019
Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation.
Yard BD et al.
Cancer Research, 2019
Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer.
Kang YP et al.
Elife, 2019
A catalogue of somatic NRF2 gain-of-function mutations in cancer.
Kerins MJ et al.
Scientific Reports, 2018
Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder.
Huppke P et al.
Nature Communications, 2017
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.
Kim E et al.
Cancer Discovery, 2016
Cross-cancer profiling of molecular alterations within the human autophagy interaction network.
Lebovitz CB et al.
Autophagy, 2015
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2.
Cho HY
Oxidative Medicine and Cellular Longevity, 2013
NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.
Shibata T et al.
Neoplasia (new York, N.y.), 2011